Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Patricia N Sidharta,1 Meggane Melchior,1 Martin K Kankam,2 Jasper Dingemanse1 1Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil CH-4123, Switzerland; 2Vince and Associates Clinical Research, Overland Park, KS 66211, USA Background: Aprocitentan is an orally active, dual...
Main Authors: | Sidharta PN, Melchior M, Kankam MK, Dingemanse J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-03-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/single--and-multiple-dose-tolerability-safety-pharmacokinetics-and-pha-peer-reviewed-article-DDDT |
Similar Items
-
Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
by: Pierre-Eric Juif, et al.
Published: (2021-02-01) -
Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
by: Jiří Patočka, et al.
Published: (2005-01-01) -
Endothelin receptor antagonists
– a brief description of the new class of drugs
by: Agata Kowalczyk, et al.
Published: (2014-01-01) -
Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
by: Suhas Vasaikar, et al.
Published: (2018-02-01) -
Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
by: N A Tsareva
Published: (2013-12-01)